BCL2 and colorectal carcinoma: To identify the best BH3 mimetic strategy, we analyzed mRNA ratios of MCL1 and BCL-XL, based on a previous study that showed a low ratio of MCL1:BCL-XL, in colorectal cancer (CRC) correlated with synthetic lethality between ERK pathway inhibitors and pan BCL-2 inhibitors [28].